The search for maturity…  by Turmel-Rodrigues, L.U.C.
Letters to the Editor 1289
Needless to say of course, that accumulation of collected
Fabry Registry data will contribute to evidence-based
care.
Regarding the comment on Fabry disease in women,
I agree that with time there is an increasing recognition
of clinical manifestations of the disease in female het-
erozygotes, and as I mentioned in the Forum discussion,
genetic and nongenetic factors can influence the sever-
ity and progression of the outcome. Although no females
have been included in the two large clinical trials (as ref-
erenced in the Forum and also cited by Dr. Kleinert et al),
it is also suggested that carriers with substantial disease
manifestations should be treated with ERT [2].
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The search for maturity. . .
To the Editor: Recently, my American colleagues pub-
lished results in the treatment of nonmaturing fistulas.
Their views differ from mine, and they referred to my
publications in a derogatory fashion [1]. I wrote that a
stenosis is diagnosed in all cases of delayed maturation
[2]. In 1997, Beathard diagnosed stenosis in 33% of cases
[3], and this rate has now skyrocketed to 78%. There is
no doubt that he will reach my rate of 100% in a future
article. He would first have to perform angiograms by ar-
terial puncture at the elbow to diagnose stenoses located
in proximal arteries.
I wrote that there is no opacification of collaterals with-
out stenosis of the main outflow vein. Figure 2 of Beat-
hard’s article is very informative because it shows an an-
giogram before occlusion of a tributary, but the authors
overlook the stenosis of the main vein, which explains
why this collateral was opacified (Fig. 1) [1].
Figure 1B [1] of the article shows that dilation of the
vein caused stenosis in the artery, which the authors over-
looked, and I am skeptical about the ability of this fis-
tula to deliver sufficient flow. This case should have been
treated by surgical creation of a new anastomosis, which
leads to higher patency rates [4].
Finally, the authors report amazingly high patency rates
and compare them to mine in a derogatory manner. I
treated truly immature fistulas with a mean age of 2.5
months compared with 4.5 in their article, and I salvaged
thrombosed fistulas, whereas they did not.
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Differential diagnosis between
X-linked Alport syndrome and
thin basement membrane
nephropathy
To the Editor: We read with interest the edito-
rial by Gregory [1] to the article “COL4A3 mutations
and their clinical consequences in thin basement mem-
brane nephropathy (TBMN).” Correctly, the necessity is
stressed to clearly distinguish thin basement membrane
nephropathy (TBMN) from Alport syndrome (AS), es-
pecially when the family history of renal failure and deaf-
ness is lacking. We believe that some complementary in-
formation should be given.
When renal biopsy is not typical [only thin glomerular
basement membrane (GBM)], the immunohistochem-
istry evaluation for a(IV) chains in the GBM can eas-
ily distinguish TBMN from Alport syndrome because in
the latter a3/a4/a5 chains are abnormally distributed or
even absent [2, 3]. In addition, the use of skin biopsy has
been demonstrated to be a very useful tool for diagnosing
X-linked AS. The reliability of skin immunohistochem-
istry for diagnosis of X-linked AS has been estimated in
about 80% in affected males and is a smaller percentage
in female carriers [4].
Very recently, the use of confocal laser microscopy in
the examination of the epidermal basement membrane
(EBM) had been proven to be able to detect a5(IV)
